Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 10, Octobre 2012
Page(s) 852 - 857
Section Récepteurs couplés aux protéines G
DOI https://doi.org/10.1051/medsci/20122810013
Publié en ligne 12 octobre 2012
  1. Lagerström MC, Schiöth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008 ; 7 : 339–357. [CrossRef] [PubMed] [Google Scholar]
  2. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006 ; 5 : 821–834. [CrossRef] [PubMed] [Google Scholar]
  3. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010 ; 62 : 265–304. [CrossRef] [PubMed] [Google Scholar]
  4. De Amici M, Dallanoce C, Holzgrabe U, et al. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Med Res Rev 2010 ; 30 : 463–549. [PubMed] [Google Scholar]
  5. Monod JJ, Wyman J, Changeux JP. On the nature of allosteric transition: a plausible model. J Mol Biol 1965 ; 12 : 88–118. [CrossRef] [PubMed] [Google Scholar]
  6. Hall DA. Modeling the functional effects of allosteric modulators at pharmacological receptors: Extension of the two-state model of receptor activation. Mol Pharmacol 2000 ; 58 : 1412–1423. [PubMed] [Google Scholar]
  7. Costa T, Cotecchia S. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol Sci 2005 ; 26 : 618–624. [CrossRef] [PubMed] [Google Scholar]
  8. Lecat S, Bucher B, Mely Y, Galzi JL. Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J Biol Chem 2002 ; 277 : 42034–42048. [CrossRef] [PubMed] [Google Scholar]
  9. Stallaert W, Dorn JF, van der Westhuizen E, et al. Impedance responses reveal beta2-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One 2012 ; 7 : 1–14. [CrossRef] [PubMed] [Google Scholar]
  10. Congreve M, Langmead CJ, Mason JS, Marshall FH. Progress in structure based drug design for G protein-coupled receptors. J Med Chem 2011 ; 54 : 4283–4311. [CrossRef] [PubMed] [Google Scholar]
  11. Bokoch MP, Zou Y, Rasmussen SGF, et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010 ; 463 : 108–114. [CrossRef] [PubMed] [Google Scholar]
  12. Ilien B, Glasser N, Clamme JP, et al. Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem 2009 ; 284 : 19533–19543. [CrossRef] [PubMed] [Google Scholar]
  13. Ilien B, Franchet C, Bernard P, et al. Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. J Neurochem 2003 ; 85 : 768–778. [CrossRef] [PubMed] [Google Scholar]
  14. Vollmer JY, Alix P, Chollet A, et al. Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors. J Biol Chem 1999 ; 274 : 37915–37922. [CrossRef] [PubMed] [Google Scholar]
  15. Maillet EL, Pellegrini N, Valant C, et al. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 2007 ; 21 : 2124–2134. [CrossRef] [PubMed] [Google Scholar]
  16. Palanche T, Ilien B, Zoffmann S, et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 2001 ; 276 : 34853–34861. [CrossRef] [PubMed] [Google Scholar]
  17. Sprang S. GEFs: master regulators of G-protein activation. Trends Biochem Sci 2001 ; 26 : 266–267. [CrossRef] [PubMed] [Google Scholar]
  18. Strange PG. Agonist binding to G-protein coupled receptors. Br J Pharmacol 2000 ; 129 : 820–821. [CrossRef] [PubMed] [Google Scholar]
  19. Swaminath G, Steenhuis J, Kobilka B, Lee TW. Allosteric modulation of beta2-adrenergic receptor by Zn2+. Mol Pharmacol 2002 ; 61 : 65–72. [CrossRef] [PubMed] [Google Scholar]
  20. Paila YD, Chattopadhyay A. The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction ? Glycoconj J 2009 ; 26 : 711–720. [CrossRef] [PubMed] [Google Scholar]
  21. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharm Ther 2004 ; 103 : 203–221. [CrossRef] [PubMed] [Google Scholar]
  22. Janz JM, Ren Y, Looby R, et al. Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. J Am Chem Soc 2011 ; 133 : 15878–15881. [CrossRef] [PubMed] [Google Scholar]
  23. Birdsall NJM, Lazareno S. Allosterism at muscarinic receptors: Ligands and mechanisms. Mini-Rev Med Chem 2005 ; 33 : 523–543. [CrossRef] [Google Scholar]
  24. Digby GJ, Shirey JK, Conn PJ. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 2010 ; 6 : 1345–1354. [CrossRef] [PubMed] [Google Scholar]
  25. Mohr K, Tränkle C, Kostenis E, et al. Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010 ; 159 : 997–1008. [CrossRef] [PubMed] [Google Scholar]
  26. Tahtaoui C, Parrot I, Klotz P, et al. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem 2004 ; 47 : 4300–4315. [CrossRef] [PubMed] [Google Scholar]
  27. Valant C, Maillet E, Bourguignon JJ, et al. Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration. J Med Chem 2009 ; 52 : 5999–6011. [CrossRef] [PubMed] [Google Scholar]
  28. Urwyler S. Allosteric modulation of Family C G-protein-coupled receptors : From molecular insights to therapeutic perspectives. Pharmacol Rev 2011 ; 63 : 59–126. [CrossRef] [PubMed] [Google Scholar]
  29. Goudet C, Gaven F, Kniazeff J, et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 2004 ; 101 : 378–383. [CrossRef] [PubMed] [Google Scholar]
  30. Schann S, Mayer S, Franchet C, et al. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J Med Chem 2010 ; 53 : 8775–8779. [CrossRef] [PubMed] [Google Scholar]
  31. Sebag JA, Pantel J. Ciblage thérapeutique des récepteurs couplés aux protéines G : la voie allostérique. Med Sci (Paris) 2012 ; 28 : 845–851. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Lebon G, Tate C. Les récepteurs couplés aux protéines G dans la lumière. Med Sci (Paris) 2012 ; 28 : 876–882. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Banères JL, Mouillac B. Manipulation des RCPG : expression, purification et stabilisation in vitro. Med Sci (Paris) 2012 ; 28 : 837–844. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Jockers R, Gbahou F, Tadagaki K, Kamal M. Oligomérisation des protéines humaines et virales à sept domaines transmembranaires : nouvelle stratégie virale pour manipuler la cellule hôte. Med Sci (Paris) 2012 ; 28 : 864–869. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  35. Haga K, Kruse AC, Asada H, et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012 ; 482 : 547–551. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.